<DOC>
	<DOCNO>NCT00834158</DOCNO>
	<brief_summary>A primary hepatocellular carcinoma ( HCC ) generally regard unresectable future liver remnant ( FLR ) ≤40％ total liver volume patient underlie liver disease , hepatitis B . In China , TACE common treatment unresectable HCC . Recently , PVE employ enlarge FLR patient increase resectability surgical safety major hepatectomies . In order shut arterio-portal shunt liver control tumor progress TACE sometimes perform PVE . In study design randomize control trial investigate efficacy sequential TACE PVE increase resectability hepatitis B relate HCC compare TACE alone .</brief_summary>
	<brief_title>Efficacy Sequential TACE PVE Resectability Hepatitis B Related HCC</brief_title>
	<detailed_description>In China , primary hepatocellular carcinoma ( HCC ) mostly hepatitis B related disease . The liver function patient damage , often limit execution major hepatectomy . A tumor generally regard unresectable future liver remnant ( FLR ) ≤40％ total liver volume patient underlie liver disease . In China , TACE common treatment unresectable HCC . TACE slow tumor progress little effect enlarge FLR . Recently , PVE employ enlarge FLR patient increase resectability surgical safety major hepatectomies . But intrahepatic arterioportal shunt tumor progress decrease effect PVE . In order shut arterioportal shunt control tumor progress TACE sometimes perform PVE . In study design randomize control trial investigate efficacy sequential TACE PVE increase resectability hepatitis B relate HCC compare TACE alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1. age:2065years old ; 2. clinical diagnosis primary liver cancer , HBsAg positive , without therapy tumor ; 3. single lesion diameter &gt; 6.5cm , multiple lesion locate within half liver adjacent three lobe ; 4. estimate liver remnant volume ≤40 % 5. liver function ChildPugh class A , ALT≤80IU/l . Exclusion criterion : 1. reject attend； 2. portal vein trunk compress tumor ; 3. diffuse type cancer extensive cancer thrombus main branch PV , HV , IVC bile duct ; 4. extrahepatic metastasis ; 5. obvious portal hypertension ( moderate severe varix esophagus and/or gastric fundus , enlarge spleen , WBC &lt; 4×109／L , PLT &lt; 80×109／L ) 6. diabetes 7. allergy iodine</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Transarterial chemoembolization ( TACE )</keyword>
	<keyword>Portal vein embolization ( PVE )</keyword>
	<keyword>Surgical resection</keyword>
	<keyword>Disease-free survival</keyword>
	<keyword>Overall survival</keyword>
</DOC>